BR0307257A - Polimorfismos genéticos no gene da pré-pró-taquicinina - Google Patents

Polimorfismos genéticos no gene da pré-pró-taquicinina

Info

Publication number
BR0307257A
BR0307257A BR0307257-6A BR0307257A BR0307257A BR 0307257 A BR0307257 A BR 0307257A BR 0307257 A BR0307257 A BR 0307257A BR 0307257 A BR0307257 A BR 0307257A
Authority
BR
Brazil
Prior art keywords
gene
polymorphism
nkna
compatibility
efficacy
Prior art date
Application number
BR0307257-6A
Other languages
English (en)
Inventor
Dorothee Foernzler
Lara Hashimoto
Jia Liu
Eric Luedin
Andrew Sleight
Pierre Vankan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0307257A publication Critical patent/BR0307257A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)

Abstract

"POLIMORFISMOS GENéTICOS NO GENE DA PRéPRó-TAQUICININA". A presente invenção refere-se a um método para correlacionar polimorfismos de nucleotídeo único no gene da pré-pró-taquicinina (NKNA) com a eficácia e compatibilidade de um composto farmaceuticamente ativo administrado a um ser humano. A invenção refere-se ainda a um método para determinação da eficácia e compatibilidade de um composto farmaceuticamente ativo administrado a um ser humano, cujo método compreende a determinação de pelo menos um polimorfismo de nucleotídeo único no gene de NKNA. Os referidos métodos são baseados na determinação específica de polimorfismos de nucleotídeo único no gene de NKNA e na determinação da eficácia e compatibilidade de um composto farmaceuticamente ativo em um ser humano, mediante a referência ao polimorfismo no gene de NKNA. A invenção refere-se ainda a ácidos nucléicos isolados, compreendendo dentro de suas seq³ências os polimorfismos conforme aqui definido, a iniciadores de ácidos nucléicos e a sondas de oligonucleotídeos capazes de hibridizar tais ácidos nucléicos e a kits de diagnóstico compreendendo um ou mais de tais iniciadores e sondas para detecção de um polimorfismo no gene de NKNA, a uma embalagem farmacêutica compreendendo antagonistas do receptor NK-1 e instruções para administração dessa droga a seres humanos testados em relação ao polimorfismo, assim como a um meio de leitura em computador com informação de seq³ência armazenada para o polimorfismo no gene de NKNA.
BR0307257-6A 2002-01-31 2003-01-23 Polimorfismos genéticos no gene da pré-pró-taquicinina BR0307257A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02001937 2002-01-31
PCT/EP2003/000630 WO2003064685A2 (en) 2002-01-31 2003-01-23 Genetic polymorphisms in the preprotachykinin gene

Publications (1)

Publication Number Publication Date
BR0307257A true BR0307257A (pt) 2004-12-14

Family

ID=27635778

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307257-6A BR0307257A (pt) 2002-01-31 2003-01-23 Polimorfismos genéticos no gene da pré-pró-taquicinina

Country Status (21)

Country Link
US (2) US20030158187A1 (pt)
EP (1) EP1472377A2 (pt)
JP (1) JP2005515788A (pt)
KR (1) KR20040077910A (pt)
CN (1) CN1625603A (pt)
AR (1) AR038334A1 (pt)
BR (1) BR0307257A (pt)
CA (1) CA2473128A1 (pt)
GT (1) GT200300020A (pt)
HR (1) HRP20040669A2 (pt)
IL (1) IL162733A0 (pt)
MX (1) MXPA04007353A (pt)
NO (1) NO20043613L (pt)
PA (1) PA8564401A1 (pt)
PE (1) PE20030816A1 (pt)
PL (1) PL371731A1 (pt)
RU (1) RU2004126440A (pt)
TW (1) TW200302729A (pt)
UY (1) UY27634A1 (pt)
WO (1) WO2003064685A2 (pt)
ZA (1) ZA200405516B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE500224T1 (de) 2004-07-06 2011-03-15 Hoffmann La Roche Herstellungsverfahren für carboxamid-pyridin- derivate als zwischenprodukte bei der synthese von nk-1-rezeptor-antagonisten
CN102449166B (zh) * 2009-05-26 2013-12-04 厦门大学 一种单管检测多个单核苷酸变异或单核苷酸多态性的方法
TR201901828T4 (tr) * 2013-01-08 2019-03-21 Sphingotec Gmbh Bir kişide kanser olma veya kanser tanısı konma riskinin öngörüsü için bir usul.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8613431D0 (en) * 1986-06-03 1986-07-09 Medical Res Council Human tachykinins
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
AU5052599A (en) * 1998-07-25 2000-02-21 Astrazeneca Ab Genetic polymorphisms in the human neurokinin 2 receptor gene and their use in diagnosis and treatment of diseases
PT1103545E (pt) * 1999-11-29 2004-03-31 Hoffmann La Roche 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof

Also Published As

Publication number Publication date
US20030158187A1 (en) 2003-08-21
PL371731A1 (en) 2005-06-27
WO2003064685A3 (en) 2003-12-24
RU2004126440A (ru) 2005-08-10
PA8564401A1 (es) 2004-03-26
IL162733A0 (en) 2005-11-20
CA2473128A1 (en) 2003-08-07
CN1625603A (zh) 2005-06-08
JP2005515788A (ja) 2005-06-02
GT200300020A (es) 2003-12-23
AR038334A1 (es) 2005-01-12
TW200302729A (en) 2003-08-16
EP1472377A2 (en) 2004-11-03
MXPA04007353A (es) 2004-11-26
UY27634A1 (es) 2003-07-31
ZA200405516B (en) 2005-07-01
HRP20040669A2 (en) 2005-06-30
KR20040077910A (ko) 2004-09-07
PE20030816A1 (es) 2003-10-28
US20060228752A1 (en) 2006-10-12
NO20043613L (no) 2004-08-30
WO2003064685A2 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
US11913073B2 (en) Methods for assessing risk of developing a viral disease using a genetic test
EP1290220B1 (en) Genetic diagnosis of qt prolongations as adverse drug reactions
US20240052418A1 (en) Method for predicting a subject's response to slc modulator therapy
US11041207B2 (en) Method for predicting a subject's response to valproic acid therapy
JP2009521904A (ja) 狭窄に関連する一塩基多型、その検出方法および使用
EP3325661B1 (en) Fgfr expression and susceptibility to an fgfr inhibitor
US20100144781A1 (en) Methods of treating psychosis and schizophrenia based on polymorphisms in the erbb4 gene
ATE416183T1 (de) Oligonukleotide mit alternierenden segmenten und deren verwendungen
JP2009523404A (ja) 慢性関節リウマチに関連する遺伝的多型、その検出方法および使用
EP2841595A2 (en) Genetic predictors of response to treatment with crhr1 antagonists
RU2009147281A (ru) Способы и композиции для диагностики и лечения волчанки
US20080166723A1 (en) CDK5 genetic markers associated with galantamine response
US20180256521A1 (en) Multiple myeloma treatment
CA3097874A1 (en) Methods and systems for characterizing severe crohn's disease
BR0307257A (pt) Polimorfismos genéticos no gene da pré-pró-taquicinina
US20040248286A1 (en) Nucleic acid molecules that are differentially regulated in a bipolar disorder and uses thereof
JPWO2005028647A1 (ja) 核酸プローブ、核酸チップ、標的核酸検出方法、薬剤スクリーニング方法、標的核酸検出装置及び遺伝子診断方法
EP3277835B1 (en) Genetic predictors of a response to treatment with crhr1 antagonists
CA3200256A1 (en) Methods and systems of stratifying inflammatory disease patients
MX2007012170A (es) Polimorfismos del gen de la enfermedad c1 tipo de nieman pick (npc1l1), y metodos de uso de los mismos.
US20210196751A1 (en) Methods of cancer treatment using an atr inhibitor
CN101886129A (zh) 高血压易感基因AGTR1单核苷酸多态性位点rs388915的检测方法及检测试剂盒
JP2007510404A (ja) アルツハイマー病の発症年齢に関連するｎｔｒｋ１遺伝子マーカー
EP3405589A1 (en) Method of detecting and treating p. acnes and kit thereof
US20170073753A1 (en) Methods and kits for treating and classifying individuals

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O, 6O E 7O ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2047 DE 30/03/2010.